Grandl, Gerald
Collden, Gustav
Feng, Jin http://orcid.org/0000-0001-7265-0051
Bhattacharya, Sreya
Klingelhuber, Felix http://orcid.org/0000-0002-0034-6170
Schomann, Leopold
Bilekova, Sara http://orcid.org/0000-0001-6699-1386
Ansarullah, http://orcid.org/0000-0002-3415-7319
Xu, Weiwei http://orcid.org/0000-0002-8723-0778
Far, Fataneh Fathi
Tost, Monica
Gruber, Tim
Bastidas-Ponce, Aimée
Zhang, Qian
Novikoff, Aaron http://orcid.org/0000-0002-4838-001X
Liskiewicz, Arkadiusz http://orcid.org/0000-0002-4102-5373
Liskiewicz, Daniela http://orcid.org/0000-0002-5859-6316
Garcia-Caceres, Cristina
Feuchtinger, Annette
Tschöp, Matthias H. http://orcid.org/0000-0002-4744-371X
Krahmer, Natalie
Lickert, Heiko http://orcid.org/0000-0002-4597-8825
Müller, Timo D. http://orcid.org/0000-0002-0624-9339
Article History
Received: 28 March 2022
Accepted: 19 January 2024
First Online: 28 February 2024
Competing interests
: M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals, Cambridge, MA. He was a member of the Research Cluster Advisory Panel of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016), and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018) and, since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to, pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München such as WO/2016/188932 A2 or WO/2017/194499 A1. M.H.T. confirms that, to the best of his knowledge, none of the above funding sources was involved in the preparation of the present paper. T.D.M. receives research funding from Novo Nordisk and has received speaking fees from Eli Lilly, AstraZeneca, Novo Nordisk and Merck. H.L. is cofounder of the Viacure GmbH and has ownership interest. H.L. is the inventor of the patent ‘Novel IGFR-like receptor and uses thereof’ held by the Helmholtz Zentrum München GmbH (WO2017042242) and co-inventor of the pending patent application filed by the Helmholtz Zentrum München GmbH ‘Novel IGFR-like 1 monoclonal antibodies and uses thereof’ (WO2023002060). The other authors declare no competing interests.